FI117509B - Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan - Google Patents

Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan Download PDF

Info

Publication number
FI117509B
FI117509B FI962958A FI962958A FI117509B FI 117509 B FI117509 B FI 117509B FI 962958 A FI962958 A FI 962958A FI 962958 A FI962958 A FI 962958A FI 117509 B FI117509 B FI 117509B
Authority
FI
Finland
Prior art keywords
humanized
ser
sequence
human
gly
Prior art date
Application number
FI962958A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962958A (fi
FI962958A0 (fi
Inventor
Jose Saldanha
Mary M Bendig
Olivier J Leger
Tarran S Jones
Ted A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of FI962958A0 publication Critical patent/FI962958A0/fi
Publication of FI962958A publication Critical patent/FI962958A/fi
Application granted granted Critical
Publication of FI117509B publication Critical patent/FI117509B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
FI962958A 1994-01-25 1996-07-24 Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan FI117509B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US18626994 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4
US9501219 1995-01-25

Publications (3)

Publication Number Publication Date
FI962958A0 FI962958A0 (fi) 1996-07-24
FI962958A FI962958A (fi) 1996-09-24
FI117509B true FI117509B (fi) 2006-11-15

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962958A FI117509B (fi) 1994-01-25 1996-07-24 Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan

Country Status (21)

Country Link
EP (2) EP1759709B1 (no)
JP (5) JP4115517B2 (no)
KR (1) KR100367948B1 (no)
CN (1) CN1211123C (no)
AT (1) ATE333895T1 (no)
AU (1) AU703152B2 (no)
CA (1) CA2182013C (no)
DE (2) DE122006000043I1 (no)
DK (2) DK1759709T3 (no)
ES (2) ES2424292T3 (no)
FI (1) FI117509B (no)
FR (1) FR06C0024I2 (no)
HU (1) HU220799B1 (no)
LU (1) LU91271I2 (no)
MX (1) MX9602971A (no)
NL (1) NL300238I2 (no)
NO (3) NO319867B1 (no)
NZ (1) NZ279730A (no)
PL (1) PL181827B1 (no)
PT (1) PT804237E (no)
WO (1) WO1995019790A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
NZ262615A (en) * 1993-02-09 1996-02-27 Biogen Inc Treating insulin dependent diabetes (type i) with anti vla4 (very late antigen) antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
JP5483515B2 (ja) * 1999-04-22 2014-05-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EA011384B1 (ru) 1999-06-01 2009-02-27 Байоджен Айдек Ма Инк. Способ лечения воспалительного заболевания
EP2140881B1 (en) * 1999-12-16 2013-04-17 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
YU80903A (sh) 2001-04-13 2006-05-25 Biogen Inc. Antitela vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
AU2005306399B2 (en) * 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
US10119979B2 (en) 2006-05-25 2018-11-06 Biogen Ma Inc. Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies
EP2124996A4 (en) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc METHODS OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING ALPHA-FETOPROTEIN COMBINED WITH INTEGRIN ANTAGONIST
CN103977404A (zh) * 2007-06-14 2014-08-13 比奥根艾迪克Ma公司 抗体制剂
US8066917B2 (en) 2007-12-13 2011-11-29 Tokuyama Corporation Photochromic curable composition
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
SG10201502967RA (en) 2010-04-16 2015-05-28 Biogen Ma Inc Anti-vla-4 antibodies
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
CA2153692C (en) * 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
EP0804237A1 (en) 1997-11-05
JP2009235078A (ja) 2009-10-15
DK1759709T3 (da) 2013-06-10
NL300238I1 (no) 2006-10-02
AU703152B2 (en) 1999-03-18
FR06C0024I2 (fr) 2009-01-02
CA2182013A1 (en) 1995-07-27
PL315634A1 (en) 1996-11-25
CA2182013C (en) 2007-07-17
NO2006008I1 (no) 2006-08-07
ES2270425T3 (es) 2007-04-01
PT804237E (pt) 2006-10-31
JP2013165718A (ja) 2013-08-29
PL181827B1 (pl) 2001-09-28
FR06C0024I1 (no) 2006-10-13
NO963097D0 (no) 1996-07-24
LU91271I2 (fr) 2006-10-02
JP5487382B2 (ja) 2014-05-07
NO2017040I1 (no) 2017-08-01
KR970700513A (ko) 1997-02-12
HUT75129A (en) 1997-04-28
DE122006000043I1 (de) 2007-02-15
NL300238I2 (nl) 2007-05-01
DE69535133D1 (de) 2006-09-07
JP4115517B2 (ja) 2008-07-09
JP2013173738A (ja) 2013-09-05
EP1759709B1 (en) 2013-02-27
EP0804237A4 (en) 2003-04-16
EP0804237B8 (en) 2006-11-08
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
KR100367948B1 (ko) 2003-07-12
WO1995019790A1 (en) 1995-07-27
DK0804237T3 (da) 2006-10-16
NZ279730A (en) 1998-04-27
MX9602971A (es) 1998-01-31
FI962958A (fi) 1996-09-24
JPH09508272A (ja) 1997-08-26
AU1696095A (en) 1995-08-08
ES2424292T3 (es) 2013-09-30
NO319867B1 (no) 2005-09-26
DE69535133T2 (de) 2008-08-21
NO2017040I2 (no) 2018-08-28
ATE333895T1 (de) 2006-08-15
HU9602019D0 (en) 1996-09-30
CN1140413A (zh) 1997-01-15
EP0804237B1 (en) 2006-07-26
JP2006045237A (ja) 2006-02-16
HU220799B1 (hu) 2002-05-28
CN1211123C (zh) 2005-07-20
NO963097L (no) 1996-09-24
FI962958A0 (fi) 1996-07-24

Similar Documents

Publication Publication Date Title
FI117509B (fi) Humanisoituja vasta-aineita leukosyyttitarttumismolekyyliä VLA-4 vastaan
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
US6407214B1 (en) Antibodies against E-selectin
AU747898B2 (en) Monoclonal antibodies to human CD6
CA2153692C (en) Recombinant anti-vla4 antibody molecules
CN101134779B (zh) 人cd22特异性抗体及其治疗和诊断应用
AU4032299A (en) Fap alpha-specific antibody with improved producibility
JP2001507210A (ja) α４β７インテグリンと反応するヒト化免疫グロブリン
HUE029824T2 (en) New anti-GPVI antagonist antibodies, Fab fragments, and applications
US20200002410A1 (en) Methods and compositions for imaging amyloid deposits
MXPA99001462A (es) Inmunoglobulina humanizada reactiva con (alfa4beta7) integrina

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117509

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060016

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 300

Extension date: 20200125

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20060016

PC Transfer of assignment of patent

Owner name: BIOGEN MA INC.